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Gestational Trophoblastic Diseases are a spectrum of 
interrelated disorders that arise from abnormal 
pregnancy and are characterized by excessive 
elevation of Human Chorionic Gonadotrophins. 
They include both benign and malignant forms; 
hydatidiform mole, Invasive mole, Placental Site 
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ABSTRACT
Context Gestational Trophoblastic Diseases are a spectrum of interrelated diseases disorders that arise from 
abnormal pregnancy and are characterized by excessive elevation of Human Chorionic Gonadotrophins. 
They include both benign and malignant forms; hydatidiform mole, Invasive mole, Placental Site 
Trophoblastic (PSTT) tumour and Choriocarcinoma. 
Objective: The objective of this study was to present the outcomes and challenges encountered in the 
management of GTDs in a tertiary centre in South-western part of Nigeria.
Study Design, Setting and Subjects: This was a retrospective study of the cases of gestational trophoblastic 
disease managed at Obafemi Awolowo University Teaching hospitals complex, Ile Ife between 2009 and 
2013. Data were retrieved from the case records and telephone calls were put across the patients to enquire 
about the state of health of the patients. Data was analysed using SPSS version 20.
Main Outcome Measures: The main outcome measures were the incidence of GTDs, outcomes and 
challenges encountered in the management of patients with gestational trophoblastic disease.
Results: A total of 27 women were managed for GTDs; 22 had hydatidiform moles and 5 were managed for 
choriocarcinoma. The mean age of the patients was 31.9 years SD 6.94, mean parity 2 SD 1.53; mean 
duration of amenorrhoea was 15.7 weeks SD 4.92. The most common presenting symptom was vaginal 
bleeding in 81.5% of cases. Non-adherence to prescribed treatment was high as over half of the patients with 
molar pregnancy was lost to follow up after molar evacuation. Mortality was also high among patients with 
GTDs as 60% of the patients with choriocarcinoma died during treatment.
INTRODUCTION
143
ear ly  ins t i tu t ion  of  chemotherapy for  
choriocarcinoma with careful follow up with serum 
beta HCG monitoring have transformed what used 
to be a highly fatal disease to one that is curable with 
preservation of reproductive functions. GTDs have 
a higher cure rate relative to other gynaecological 
malignancies. However, achieving this requires 
long term follow up monitoring with serum â HcG. 
Patients must also adhere to the treatment plan by 
coming for regular check for early detection of 
recurrences in addition to avoid getting pregnant 
during the follow up period.This is best achieved in 
specialized centres dedicated to the management of 
this condition. Oncological services are poorly 
developed in many developing countries and as 
such specialized centres are virtually non-existent.
MATERIALS AND METHODS
The medical records of patients who managed for 
GTDs between January 2009 and December 2013 
were retrieved from the medical records department 
of the hospital. The socio-demographic factors such 
as age, parity, contraceptive usage and marital 
status and clinical factors and results of laboratory 
investigations including pathological results such 
as presenting symptoms, period of amenorrhoea, 
uterine size at presentation, duration of symptoms 
before presenting to the hospital, administration of 
chemotherapy, duration of follow up and outcome 
of management were retrieved from the case files. 
Telephone calls were made to patients and relations 
to enquire about the state of health of patients and to 
remind them to come for their chemotherapy. The 
retrieved data was entered into a proforma designed 
for the study. Analysis was done by SPSS version 
20.
RESULTS
During this study period, 27 women were managed 
for GTD; 22 patients with molar pregnancies and 5 
Trophoblastic (PSTT) tumour and Choriocarcinoma. 
Hydatidiform mole or molar pregnancy is divided 
into two; complete and partial moles. Complete 
moles have diploid karyotype because they 
commonly arise by arise as a results of fertilization of 
an enucleated ovum by a haploid spermatozoon 
which subsequently duplicates it's chromosomal. 
They lack maternal genetic contents.  Partial moles 
on the other hand are triploid because they contain an 
extra chromosome which is obtained from the father.  
Though considered benign form of GTDs, molar 
pregnancies could at the same time be considered 
premalignant because of the propensity to transform 
into the malignant form which is choriocarcinoma.  
The risk of malignant transformation is greater with 
1.
complete moles
The incidence of GTDs has been reported to show 
racial and geographical variations in many several 
2,3
epidemiological studies.  with higher incidences 
being reported from Asian and African countries 
compared with European and North American 
4-7
countries.  Even migrants to European countries 
where the incidence is low have been shown to have 
8
higher incidence than the indigenous populations.  In 
addition to racial factors, reproductive factors have 
been implicated in the risk of developing GTDs.  
Extreme of reproductive age and history of previous 
molar pregnancy have been shown to be associated 
9-12
with increased risk of developing GTDs.
Due to early diagnosis, most patients with molar 
pregnancy presents with symptoms of missed 
abortion such as vaginal bleeding. Other clinical 
features include exaggerated symptoms of 
pregnancy probably due to the excessive HCG 
production, rare presentations may include signs of 
hyperthyroidism and pre eclampsia.
In the past GTDs were invariably fatal due to late 
diagnosis but with the advent of ultrasonography 
early diagnosis is common. Prompt management 
with suction evacuation for molar pregnancies and 
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defaulted during the period of follow up (Table 4). 
The average number of visit was 3.6 and the mean 
duration of follow up was 148 days (1 to 1095 days)
There was a high mortality associated with the 
management of GTDs in our centre as 4 patients 
were known to have died of the disease while on 
admission; 3 of these patients had choriocarcinoma 
patients (60%) and one patient with molar 
pregnancy (6%). Pre eclampsia, a known 
complication of molar pregnancy was found in only 
one patient (3.7%).
Preservation of reproductive function was high 
among the patients who adhered to the follow up 
plan with prompt return of menstrual functions; 
though one patient had Asherman's syndrome and 
was managed with hysteroscopic adhesiolysis. Of 
the 5 patients that were followed up for more than 
one year following molar evacuation, four of them 
(80%)had normal intrauterine pregnancy with three 
delivering at term.
DISCUSSION
Hydatidiform mole was the most common GTD 
13.managed in our centre. In our centre, partial mole 
was the most common molar pregnancy unlike the 
study in Iraq in which the complete mole comprised 
80% of the molar pregnancy managed in one 
14centre . In this study the majority of the GTDs 
(82%) managed in this study was molar pregnancy 
while choriocarcinoma comprises only 18% of the 
total number of GTD.There was no invasive mole 
or placental site trophoblastic tumour.The 
incidence of gestational trophoblastic diseases in 
this study was 4.3 per 1000 deliveries, while the 
incidence of molar pregnancy was 3.5 per 1000 
deliveries.  The incidence of choriocarcinoma was 
0.78 per 1000 deliveries. Though this is an 
institutional study, the figures are higher than the 
ones reported from Caucasian countries, they are 
with choriocarcinoma. Majority of the molar 
pregnancies were partial moles (51%) (Table 1). 
There was a total of 6347 deliveries in the hospital 
during the study period. The mean age of the patients 
was 31.9 years SD 6.94, mean parity 2 SD 1.53; 
mean duration of amenorrhoea was 15.7 weeks SD 
4.92. Most of the patients (60%) were within the age 
group 25 to 34 years. Patients with molar 
pregnancies were younger compared with those with 
choriocarcinoma with a mean age of 30.6 years 
against 34 years, however, this was not significant 
(p=0.84).  The mean number of pregnancy per 
woman was 3.3 and the mean number of delivery was 
2. The most common presenting symptom was 
vaginal bleeding in 81.5% of cases (Table 2). Late 
presentation was common as the mean duration of 
symptoms before presenting to the hospital was 21.5 
days. 
Uterine size was larger than the period of 
amenorrhoea in 14/27 (51.9%), small for date in 1 
(3.7%) and appropriate for date in 12 (44%) patients. 
Only one (3.7%) patient with complete mole had pre-
eclampsia. 
Of the 22 patients managed for molar pregnancy with 
suction evacuation during this study period,17 (77.3) 
had normalization of serum âHCG following suction 
evacuation while 5patients (22.7%) had persistent 
trophoblastic diseases. A total of nine (33%) of the 
patients received chemotherapy; 4 patients with 
persistent trophoblastic diseases following molar 
evacuation and 5 patients with choriocarcinoma.  
The patients with persistent trophoblastic disease 
received single agent chemotherapy; (3 MTX, one 
Actinomycin D). The patients with choriocarcinoma 
received combination chemotherapy in the form of 
EMACO (Table 3)
Non adherence to prescribed treatment and follow up 
was high as 45% of patients with molar pregnancy 
were never seen again at the hospital following 
evacuation.  Of the remaining patients 59% 
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peak incidence was in women within the 25 – 29 age 
group and this group constitutes 50% of the women 
in this study. The next major age group was 30 to 34 
years (25%). All patients were within the 
reproductive age group with exception of one 
patient (5%)who was above 50 years. In Malaysia, 
the mean age of women with molar was 32.0 ± 7.9 
22years. We found no statistical significant 
difference between the ages of the women with 
molar pregnancy and choriocarcinoma.
Large for date uterus is one of the risk factors for 
23, 24persistent trophoblastic disease. In the study by 
22Nirmala et al,  only 17.6% of the patients had large 
for date uterus while in this study 51% of patients 
22had large for date uterus.  The higher incidence of 
persistent trophoblastic disease seen in this study 
may not be unconnected with the higher number of 
patients with large for date uterus (51%) observed 
22in this study. In the study by Nirmala et al , 17.6% 
of the patients had large for date uterus and the 
incidence of persistent trophoblastic disease was 
223.9%.
One of the problems associated with the 
management of malignancy in many developing 
countries is late presentation and poor compliance 
25with management plan.  Patients present late due to 
ignorance, poverty, myths and superstitions 
associated with malignancies. In the absence of 
universal health insurance, the most common mode 
of payment in both public and private hospitals in 
Nigeria is out of pocket which limits access and 
affordability.  With increasing poverty, most 
women cannot afford the high cost of investigations 
and payment associated with malignancies. 
Moreover, cancer is almost synonymous with death 
in many developing countries.Late presentation is 
associated with higher incidence of complications 
and poor outcomes in patients with GTDs. For 
successful outcomes of molar pregnancy and to 
prevent complications, early diagnosis is essential 
however lower than the reported figures from Asian 
1
countries of 1 in 100 to 300 deliveries . 
7
In a 5-year study by Mbamara et al  in Eastern part of 
Nigeria, the majority of GTDs (66%) was 
7
choriocarcinoma. Findings similar to our study was 
seen in Istanbul, Turkey, where the majority of GTDs 
15
managed (97%) was hydatidiform moles. In another 
part of Turkey, Tokat province, 73 cases of GTDs 
managed over a period of 8 years were all were 
16
hydatidiform moles.
Incidence of GTD vary across countries and even 
within the same geographic zone, different 
15
incidences were reported. Results from several 
centres in Nigeria also confirms that the incidence of 
GTD varies in different parts of countries. In an 8-
year review done by Jimoh et al, in North-central 
Nigeria, an incidence of 4.1 per 1000 deliveries 
17
which was similar to the findings from this study.  
The incidence from this study was also similar to the 
7
study carried out by Mbamara et al  in Eastern 
Nigeriabut lower than the incidence in Northern 
7,18
central part of Nigeria by Amaka. The different 
incidences reported may be due to different case 
definitions and use of hospital data instead of 
population-based data.
The most common presentation in this study was 
vaginal bleeding (85%). This is not surprising as 
most patients with molar pregnancy presented as 
complications of early pregnancy. This mode of 
presentation was also the findings of studies done in 
17, 20
other parts of Nigeria. In Malaysia, in a study by 
21
Audu et al, vaginal bleeding was the most common 
presenting symptom in 95% of 102 women studied.  
Age is an important reproductive factor influencing 
the risk of GTD. According to Parazzini et 
9
al, extreme of reproductive age has been linked with 
19
development of molar pregnancy.  In a 10-year 
review by Audu at al, the peak age of incidence of 
21
molar pregnancy was 17.5 years.  However, in this 
study, none of the patient was less than 20 years,the 
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with high cure rate in Western countries, sadly this 
type of success cannot be replicated in our 
environment due to a combination of ignorance and 
poverty which makes compliance with treatment 
difficult. Specialized centres should be established 
as this is the case in more advanced countries to 
manage GTD. This will enable health care 
providers to acquire the expertise due to 
accumulation of experience.  In addition, public 
education and subsidizing cost of managing 
malignancies by the government will no doubt 
encourage many patients to present early and to 
comply with management plan.
in the management of patients with GTDS.  Despite 
the fact that majority of the patients had vagina 
bleeding after periods of amenorrhoea, late 
presentation was common.The mean duration of 
presentation was 21.5 days after the onset of 
symptoms.
The incidence of pre eclampsia in this study was low 
as only one patient had this complication. Unlike the 
26
study by Egwuata et al  in which preeclampsia 
occurred in 27% .GTD is one of the few human 
27
malignancies that are curable.  Irrespective of the 
type of GTDs, long time monitoring is required even 
after the patient had attained remissionbecause most 
recur rences  occur  wi th in  the  f i r s t  s ix  
28
months. During the period of follow up, patients and 
the partners are counseled to avoid pregnancy. In 
order to achieve this, effective contraception is 
offered. In this study, adherence to treatment plan 
was poor. Majority of the patients especially with 
hydatidiform moles defaulted after molar evacuation 
while the patients with choriocarcinoma did not 
complete the full course of prescribed chemotherapy 
due to inability to afford the drugs. Poor compliance 
with chemotherapy was also high as two of the 
patients with choriocarcinoma did not received any 
chemotherapy, one had one cycle, one also had two 
cycles while only one patient with choriocarcinoma 
had 4 cycles of chemotherapy. Many of them also 
could not appreciate the importance of prolonged 
follow up despite counselling and explanation. In the 
absence of symptoms such as vaginal bleeding with 
which many of them presented with, they had the 
illusion that 'all was well'. The combination of 
poverty and illiteracy contributed to the high 
mortality seen in this study. The reproductive 
outcome was good for patients that complied with 
the follow up regimen. Four of the women were able 
to get pregnant with three of them having term 
deliveries.
In conclusion, though GTD are a group of disease 
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Table 1: Types Of Gtd
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Table 3: Antecedent Pregnancy













Total 27 100.00 
 
147
8. Tham BW, Everard JE, Tidy JA, Drew D 
and Hancock BW. Gestational trophoblastic 
disease in the Asian population of Northern 
England and North Wales. BJOG 
2003;110(6):555-559.
9. Parazzini F, LaVecchia C, Pampallona S. 
Parental age and risk of complete and partial 
hydatidiform mole. Br J Obstet Gynecol 
1986; 93:582-585.
10. Sebire NJ, Foskett M, Fisher RA, et al. Risk 
of partial and complete molar pregnancy in 
relation to maternal age. Br J Obstet 
Gynecol 2002; 109:99-102.
11. Schorge JO, Goldstein DP, Bernstein MR, 
Berkowitz RS. Recent advances in 
gestational trophoblastic disease. J Reprod 
Med 2000; 45(9):692-700.
12. Bandy LC, Clarke-Pearson DL, Hammond 
CB. Malignant potential of gestational 
trophoblastic disease at the extreme ages of 
reproductive life. Obstet Gynecol 1984; 
64(3):395-399.
13. Soares PD, Maestá I, Costa OL, Charry RC, 
Dias A, Rudge MV. Geographical 
d i s t r i b u t i o n  a n d  d e m o g r a p h i c  
characteristics of gestational trophoblastic 
disease. J Reprod Med 2010. 55(7-8):305-
310.
14. Zhraa AT. A Prospective Study of 
Gestational Trophoblastic Disease in Al-
Mosul City. IPMJ 2013; 12(22): 268-276.
15. Ayþe Ender Yumru, Burcu Dinçgez, Banu 
Ö n d e þ ,  A b d u l h a m i t  B o z y i ð i t .  
Epidemiologic Characteristics and 
Management of Subjects Who Were 
Diagnosed with Trophoblastic Disease.  
Erciyes Med J 2012; 34(3): 106-110.
16. Bülent Çakmak, Muhammet Toprak, 
Mehmet Can Nacar, Reþid Doðan 
Köseoðlu, Nihan Güneri. Incidence of 
REFERENCES
1. Lurain JR, Brewer JI, Torok EE, Halpern B. 
Natural history of hydatidiform mole after 
primary evacuation. Am J Obstet Gynecol 
1983; 145(5):591-595.
2. Palmer JR. Advances in the epidemiology of 
gestational trophoblastic disease. J Reprod 
Med 1994;39:155-162.
3. Grimes DA. Epidemiology of gestational 
trophoblastic disease. Am J Obstet Gynecol 
1984; 150(3):309-311.
4. Atrash HK, Hogue CJR, Grimes DA. 
Epidemiology of hydatidiform mole during 
early gestation. Am J Obstet Gynecol 1986; 
154:906-909.
5. Bagshawe KD, Dent J, Webb J. Hydatidiform 
mole in England and Wales 1973-1983. 
Lancet 1986; 2:673-677.
6. Takeuchi S. Incidence of gestational 
trophoblastic disease by regional registration 
in Japan.  Hum Reprod 1987; 2:729-34.
7. Mbamara et al. Gestational Trophoblastic 
Disease in a Tertiary Hospital in Nnewi 
South east Nigeria. Niger Med J 2009; 50(4): 
87–89.
Trop J Obstet Gynaecol, 32 (1), April 2015
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